Advanced search
Publication Cover
Toxicology Communications Volume 1, 2017 - Issue 1
Submit an article Journal homepage
1,241
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Canagliflozin-associated diabetic ketoacidosis: a case report

Peter R. ChaiDepartment of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, U.S.AORCID Iconhttp://orcid.org/0000-0003-0955-4117
ORCID Icon,
Caitlin BonneyDepartment of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, U.S.A
,
Eike BlohmDivision of Medical Toxicology, Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, U.S.ACorrespondence[email protected]
,
Edward W. BoyerDepartment of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, U.S.AORCID Iconhttp://orcid.org/0000-0002-3454-1310
ORCID Icon &
Kavita M. BabuDivision of Medical Toxicology, Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, U.S.A
Pages 2-5 | Published online: 25 May 2017

References

  • Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680–1686.
  • Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–794.
  • Chao, EC. SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes. 2014;32(1):4–11.
  • Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512–517.
  • DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14.
  • Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–3434.
  • Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Investigation. 1971;28(1):101–109.
  • Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel c-glucoside with Thiophene Ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus(1). J Med Chem. 2010;53(17):6355–6360.
  • Devineni D, Polidori D. Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose Co-transporter 2 inhibitor. Clin Pharmacokinet. 2015;54(10):1027–1041.
  • Doggrell SA, McIntyre K. Canagliflozin – something new for type 2 diabetes, but is it safe and efficacious? Expert Opin Pharmacother. 2014;15(3):437–441.
  • Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16(11):1087–1095.
  • Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care [Internet]. 2015;38(12):2258–2265. Available from: http://care.diabetesjournals.org/lookup/doi/10.2337/dc15-1730
  • Trachuk P, Shihadeh S, Choi E. Euglycemic diabetic ketoacidosis in a patient on canagliflozin. Chest. 2015;148(4):257A, 257B.
  • Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302(1):R75–R83.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.